Rhythm Pharmaceuticals Inc

RYTM remains in a Stage 2 advancing uptrend with higher highs and higher lows riding above rising EMAs. Recent price action shows a mild pullback into the rising 9EMA, offering a lower-risk entry while momentum indicators remain healthy and volume supports the trend. Overbought conditions are moderate, making now an opportune time to buy near structural support rather than chasing further extensions.

• ↑Phase 3 TRANSCEND trial showed significant BMI/hunger improvements and no major safety issues; setmelanotide now FDA/EU approved
• ↑JPMorgan initiated coverage with an overweight rating and $145 price target, implying ~42% upside
• ↓P/S ratio of 31.3x far exceeds biotech peers, flagging potential overvaluation